CG Oncology (CGON) Stock Price, News & Analysis

Company Overview

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Key Stats

• Today's Range: $27.84 to $29.07
• 50-Day Range: $27.37 to $31.01
• 52-Week Range: $25.77 to $48.05
• Volume: 369,894 shs
• Average Volume: 411,575 shs
• Market Capitalization: $2.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.14
• Consensus Rating: Buy

CG Oncology Stock Analysis - MarketRank™

CG Oncology scored higher than 36% of companies evaluated by MarketBeat, and ranked 735th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CG Oncology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.21% of the float of CG Oncology has been sold short.

Short Interest Ratio / Days to Cover

CG Oncology has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in CG Oncology has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CG Oncology does not currently pay a dividend.

Dividend Growth

CG Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.21% of the float of CG Oncology has been sold short.

Short Interest Ratio / Days to Cover

CG Oncology has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in CG Oncology has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.03

News Sentiment

CG Oncology has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for CG Oncology this week, compared to 3 articles on an average week.

MarketBeat Follows

7 people have added CG Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,664,200.00 in company stock.

Percentage Held by Institutions

Only 26.56% of the stock of CG Oncology is held by institutions.

CGON Stock Analysis - Frequently Asked Questions

How have CGON shares performed this year?

CG Oncology's stock was trading at $28.68 at the beginning of the year. Since then, CGON shares have decreased by 2.9% and is now trading at $27.85.
View the best growth stocks for 2025 here.

How were CG Oncology's earnings last quarter?

CG Oncology, Inc. (NASDAQ:CGON) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.30 million. CG Oncology had a negative trailing twelve-month return on equity of 18.97% and a negative net margin of 10,642.98%.

When did CG Oncology IPO?

CG Oncology (CGON) raised $380 million in an initial public offering on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

Who are CG Oncology's major shareholders?

CG Oncology's top institutional shareholders include Decheng Capital LLC (8.38%), Vanguard Group Inc. (7.71%), Braidwell LP (4.32%) and Foresite Capital Management VI LLC (2.92%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post.
View institutional ownership trends.

How do I buy shares of CG Oncology?

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CG Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGON
• Previous Symbol: NASDAQ:CGON
• CUSIP: N/A
• CIK: 1991792
• Web: cgoncology.com
• Phone: 949-419-6203
• Fax: N/A
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $65.14
• High Stock Price Target: $75.00
• Low Stock Price Target: $50.00
• Potential Upside/Downside: +133.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,610,000.00
• Net Margins: -10,642.98%
• Pretax Margin: -10,642.98%
• Return on Equity: -18.97%
• Return on Assets: -15.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 35.32
• Quick Ratio: 35.32

Sales & Book Value

• Annual Sales: $200,000.00
• Price / Sales: 10,588.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.94) per share
• Price / Book: -14.36

Miscellaneous

• Outstanding Shares: 76,040,000
• Free Float: N/A
• Market Cap: $2.12 billion
• Optionable: Optionable
• Beta: N/A